肝内巨噬细胞在肝纤维化发展中的双重作用及其靶向治疗研究进展  

Recent Progress in Study on the Progressive and Regressive Roles of Liver Macrophage in Hepatic Fibrosis and Its Targeted Drugs

作　　者：江静 李虎[1] 彭宗根[1] JIANG Jing;LI Hu;PENG Zong-gen(Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院北京协和医学院医药生物技术研究所,北京100050

出　　处：《中国药学杂志》2021年第23期1869-1873,共5页Chinese Pharmaceutical Journal

基　　金：国家十三五重大新药创制科技重大专项项目资助(2018ZX09711001-003-010);中国医学科学院医学与健康科技创新工程项目资助(2017-I2M-3-012)。

摘　　要：肝纤维化是各种慢性肝病进展为肝硬化的关键步骤,同时也是决定肝病预后的重要因素。肝脏内的巨噬细胞通常参与肝内免疫调节,近年来其在肝纤维化促发和消退中的作用也逐渐被明确,甚至被认为是参与肝纤维化过程的“中心调控者”,因此针对巨噬细胞进行抗肝纤维化药物的研发或可成为1种行之有效的策略。笔者对肝脏内巨噬细胞在肝纤维化进展和消退中的作用,以及涉及巨噬细胞及其相关通路的临床抗肝纤维化药物研究进展进行综述。Hepatic fibrosis is a pivotal event in the progression of various chronic liver diseases to cirrhosis,and it is also an important independent factor in determining the prognosis of liver diseases.Macrophage in the liver is usually involved in immunomodulation.In recent years,the progressive and regressive dual roles of liver macrophage in hepatic fibrosis have gradually been clarified,and thus macrophage is considered as a"central regulator".Therefore,the development of new anti-hepatic fibrosis drugs targeted at macrophages may become an attractive strategy.In this review,the dual roles of macrophages in the hepatic fibrosis are highlighted,and the clinical anti-hepatic fibrosis drugs targeted at macrophage and its related pathways are also summarized.

关 键 词：肝纤维化 巨噬细胞 发病机制 治疗药物 

分 类 号：R575.2[医药卫生—消化系统] R961[医药卫生—内科学]